-
Something wrong with this record ?
Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study
S. Gkalpakiotis, M. Arenbergerova, P. Gkalpakioti, J. Potockova, P. Arenberger, P. Kraml,
Language English Country England, Great Britain
Document type Comparative Study, Journal Article
- MeSH
- Adalimumab administration & dosage adverse effects therapeutic use MeSH
- beta 2-Glycoprotein I blood MeSH
- Biomarkers blood MeSH
- C-Reactive Protein analysis MeSH
- Vascular Cell Adhesion Molecule-1 blood MeSH
- Dermatologic Agents administration & dosage adverse effects therapeutic use MeSH
- Adult MeSH
- E-Selectin blood MeSH
- Interleukins blood MeSH
- Cardiovascular Diseases blood complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoproteins, LDL blood MeSH
- Pilot Projects MeSH
- Psoriasis blood complications drug therapy MeSH
- Risk Factors MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Healthy Volunteers MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031365
- 003
- CZ-PrNML
- 005
- 20171216103023.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/1346-8138.13661 $2 doi
- 035 __
- $a (PubMed)27774694
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
- 245 10
- $a Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study / $c S. Gkalpakiotis, M. Arenbergerova, P. Gkalpakioti, J. Potockova, P. Arenberger, P. Kraml,
- 520 9_
- $a Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
- 650 _2
- $a adalimumab $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000068879
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a kardiovaskulární nemoci $x krev $x komplikace $7 D002318
- 650 _2
- $a dermatologické látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003879
- 650 _2
- $a E-selektin $x krev $7 D019040
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdraví dobrovolníci pro lékařské studie $7 D064368
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukiny $x krev $7 D007378
- 650 _2
- $a lipoproteiny LDL $x krev $7 D008077
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a psoriáza $x krev $x komplikace $x farmakoterapie $7 D011565
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a TNF-alfa $x antagonisté a inhibitory $7 D014409
- 650 _2
- $a cévní buněčněadhezivní molekula-1 $x krev $7 D019010
- 650 _2
- $a beta-2-glykoprotein I $x krev $7 D053482
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Arenbergerová, Monika $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. $7 xx0074761 $4
- 700 1_
- $a Gkalpakioti, Petra $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Potockova, Jana $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Arenberger, Petr $u Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic. $7 nlk19990072992
- 700 1_
- $a Kraml, Pavel $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
- 773 0_
- $w MED00002635 $t The Journal of dermatology $x 1346-8138 $g Roč. 44, č. 4 (2017), s. 363-369
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27774694 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171102132151 $b ABA008
- 999 __
- $a ok $b bmc $g 1254958 $s 992392
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 44 $c 4 $d 363-369 $e 20161024 $i 1346-8138 $m Journal of dermatology $n J Dermatol $x MED00002635
- LZP __
- $a Pubmed-20171025